CASI (NASDAQ: CASI) director He Wei-Wu details share and option stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
CASI Pharmaceuticals director and over-10% holder Dr. Wei-Wu He has filed a Form 3 reporting his existing stakes in the company. He reports direct ownership of 1,910,550 Ordinary Shares and several option awards to buy additional Ordinary Shares at an exercise price of $1.93 with expirations between 2031 and 2033.
He also reports multiple indirect holdings of Ordinary Shares through entities such as Emerging Technology Partners, ETP funds, HE Family GRAT and the Huiying Memorial Foundation, and specifically disclaims beneficial ownership of shares held by the Foundation.
Positive
- None.
Negative
- None.
Insider Trade Summary
14 transactions reported
Mixed
14 txns
Insider
He Wei-Wu
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Convertible Note (right to convert) | -- | -- | -- |
| holding | Convertible Note (right to convert) | -- | -- | -- |
| holding | Convertible Note (right to convert) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
Holdings After Transaction:
Convertible Note (right to convert) — 0 shares (Indirect, See Footnote);
Option (right to buy) — 20,000 shares (Direct);
Ordinary Share — 1,910,550 shares (Direct);
Ordinary Share — 44,107 shares (Indirect, See Footnote)
Footnotes (1)
- Held by Emerging Technology Partners, LLC, a Delaware limited liability company, of which Dr. He is founder and managing partner. Held by ETP Global Fund. L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner. Held by ETP BioHealth III Fund, L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner. Held by HE Family GRAT, a grantor retained annuity trust organized under the law of Nevada for the benefit of Dr. Wei-Wu He's family members, and Dr. Wei-Wu He is the trustee of HE Family GRAT. Held by Huiying Memorial Foundation, a 501(c)(3) private family foundation under the law of Delaware and Dr. He is a member of the board of trustees and an officer of the Huiying Memorial Foundation. Dr. He does not participate in the investment decisions of the Foundation with respect to CASI's ordinary shares and disclaims beneficial ownership of CASI's ordinary shares held by Huiying Memorial Foundation. The conversion price is volume weighted average closing price of the issuer's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global Fund III L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. Pursuant to the trading price of the issuer's ordinary shares as of March 17, 2026, the amount of ordinary shares convertible under each Note is 5,000,000 (without considering accrued but unpaid interest). Held by ETP Global Fund III L.P., , a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner. Performance based options granted and exercisable upon achievement.
FAQ
What does Dr. Wei-Wu He’s Form 3 for CASI (CASI) disclose?
The Form 3 shows Dr. Wei-Wu He’s existing ownership in CASI. It lists 1,910,550 Ordinary Shares held directly, multiple option awards exercisable at $1.93 per share, and several indirect holdings through funds and family entities, including a foundation where he disclaims beneficial ownership.
What stock options in CASI does Dr. Wei-Wu He report on the Form 3?
He reports several option grants over CASI Ordinary Shares with an exercise price of $1.93 and expirations extending to 2031 and 2033. These options give him the right to buy additional shares, including grants over 300,000 and 100,000 underlying shares each.
What indirect CASI holdings are reported for Dr. Wei-Wu He?
Indirect holdings are reported through Emerging Technology Partners, ETP funds, HE Family GRAT and the Huiying Memorial Foundation. The filing notes these entities hold CASI Ordinary Shares, and it clarifies that Dr. He disclaims beneficial ownership of shares held by the Huiying Memorial Foundation.
Does Dr. Wei-Wu He hold any CASI convertible notes on this Form 3?
The filing lists several “Convertible Note (right to convert)” positions tied to CASI Ordinary Shares, held indirectly. A footnote explains the conversion price is based on a volume-weighted average, with a band between $1 and $2 per Ordinary Share for each note.